Bayoumy, Ahmed B. http://orcid.org/0000-0002-5302-9312
Ansari, A. R.
Mulder, C. J. J.
Schmiegelow, K.
Florin, Timothy
De Boer, N. K. H.
Article History
Accepted: 3 June 2024
First Online: 20 July 2024
Declarations
:
: This work is part of the Danish nation-wide research program Childhood Oncology Network Targeting Research, Organisation and Life expectancy (CONTROL) and supported by the Danish Cancer Society (R-257-A14720) and the Danish Childhood Cancer Foundation (2019-5934 and 2020-5769).
: A.B. has no conflict of interests and received no funding for the work. N.d.B. has served as a speaker for AbbVie and MSD and has served as consultant and principal investigator for TEVA Pharma BV and Takeda. He has received a (unrestricted) research grant from Dr. Falk, TEVA Pharma BV, MLDS and Takeda. All outside the submitted work. C.J.J.M. has served as consultant for HLW Pharma BV, the Netherlands and Douglas Pharma New Zealand, otherwise no conficts of interest. T.H.J.F. is a director of an Australian startup company ProdrugXtend Pty Ltd, which owns a PCT relating to thiopurines. A.R.A. has served as consultant and speaker for Dr. Falk. He has received unrestricted research grants from Janssen Cilag and MSD. K.S. is a speaker and/or Advisory Board Honoraria from Illumina (2021), Jazz Pharmaceuticals (2020, 2021, 2023), and Servier (2020, 2021, 2023); speaker fee from Amgen (2020, 2021) and Medscape (2020, 2021); Educational grants from Servier (2020, 2021, 2023); research grant from Novo Nordisk Foundation (2020,2022). Stocks in Novo Nordisk.
: Not applicable.
: Not applicable.
: Not applicable.
: The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
: Not applicable.
: Systematic search, data excretion, data synthesis, and quality assessment: Bayoumy. Meta-analysis calculations: Bayoumy. Figure and table creation: Bayoumy. Manuscript writing and reviewing: Bayoumy, Ansari, De Boer, Mulder, Florin, and Schmiegelow.